Cross-border biotech deals grow more complex as US targets China investment links (opens original article in a new tab)

Cross-border biotech deals between China and the US are becoming more complex due to US restrictions on investment and technology transfers, leading to potential modest slowdowns, but partnerships are expected to continue and grow in value.

• Cross-border biotech deals between China and the US face increased geopolitical scrutiny and regulatory hurdles.
• Industry analysts predict a modest slowdown in deals due to US restrictions on investment and technology transfers.
• Despite challenges, Western pharmaceutical companies are expected to continue partnering with Chinese biotech firms, with out-licensing agreements projected to reach $240 billion this year.